Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Modeling Bronchial Epithelium Modifications Associated With COPD Using iPS (INVECCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03181204
Recruitment Status : Recruiting
First Posted : June 8, 2017
Last Update Posted : June 11, 2018
Sponsor:
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:

The primary objective of this study is to to verify the feasibility of obtaining and comparing two epithelia in two populations based on the following experiments:

  • Differentiation of an Induced Pluripotent Stem cell (iPS) clone derived from cutaneous biopsy in a population of heavy smokers (plus patients with chronic obstructive pulmonary disease) in order to obtain differentiated bronchial epithelia in vitro.
  • For each of these same patients, generation of bronchial epithelium in vitro from bronchial biopsy using human bronchial epithelial cells (HBECs) in air-liquid interface (ALI) cultures.

Condition or disease Intervention/treatment
Pulmonary Disease, Chronic Obstructive Smoking Procedure: Bronchial biopsy Procedure: Skin biopsy Procedure: Blood sample

Detailed Description:

Secondary objectives:

  • Confrontation of the two models of in vitro generation of bronchial epithelium by iPS and ALI in order to validate our model of study of the human bronchial epithelium COPD generated by the iPS.
  • Inducing a "COPD-like" epithelial phenotype by exposing the bronchial epithelia generated from the iPS to a source of in vitro toxin (tobacco) and studying its effects by transcriptomic analysis via high-throughput sequencing (NGS) at key steps during the model.
  • Demonstrate the feasibility of obtaining iPS from peripheral blood sampling.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 16 participants
Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: Modeling Bronchial Epithelia Modifications Associated With Chronic Obstructive Pulmonary Disease (COPD) Using Induced Pluripotent Stemcells (iPS)
Actual Study Start Date : August 7, 2017
Estimated Primary Completion Date : August 7, 2019
Estimated Study Completion Date : August 7, 2019

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Patients likely to develop COPD

Patients in this group are relatively light smokers who have developed chronic obstructive lung disease (COPD).

Intervention: Bronchial biopsy

Intervention: Skin biopsy

Intervention: Blood sample

Procedure: Bronchial biopsy
The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.

Procedure: Skin biopsy
The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.

Procedure: Blood sample
The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.

Patients not likely to develop COPD

Patients in this group are heavy smokers who have no signs of chronic obstructive lung disease (COPD).

Intervention: Bronchial biopsy

Intervention: Skin biopsy

Intervention: Blood sample

Procedure: Bronchial biopsy
The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.

Procedure: Skin biopsy
The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.

Procedure: Blood sample
The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.




Primary Outcome Measures :
  1. functional bronchial epithelium from iPS? [ Time Frame: Day 0 + culture (cross-sectional study) ]
    Was a functional bronchial epithelium obtained from the patient's induced pluripotent stem cells from blood or fibroblasts? (yes/no)

  2. functional bronchial epithelium from HBEC-ALI? [ Time Frame: Day 0 + culture (cross-sectional study) ]
    Was a functional bronchial epithelium obtained from the patient's bronchial biopsy: human bronchial epithelial cell culture on an air-liquid-interface? (yes/no)


Biospecimen Retention:   Samples Without DNA
This study will general cell cultures.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This study includes patients with chronic obstructive pulmonary disease, as well as patients without chronic obstructive pulmonary disease, but who are heavy smokers.
Criteria

Inclusion Criteria for COPD patients:

  • The patient has given his/her signed, informed consent
  • Forced expiratory volume in 1 second / forced vital capacity < 0.7 [FEV1/FVC < 0.7]
  • FEV1 < 50% of predicted value
  • Exclusion of other respiratory pathologies, based on anamnesis, computed tomography and complementary respiratory function tests and transthoracic ultrasound,
  • Smoking >10 pack-years, ongoing or weaned
  • Absence of exacerbation or intercurrent infectious episode for at least 4 weeks at time of inclusion
  • Medical indication for a bronchial fibroscopy (indication validated by the physician in charge of the patient and the study investigating physician): pulmonary peripheral nodule exploration with computed tomography, interventional endoscopy for emphysema reduction, removal of foreign bodies, other indications.
  • Absence of contraindications for bronchial biopsy (left to physician's discretion): not limited to: regular intake of anticoagulants or anti-platelet aggregation, hemostasis abnormalities

Inclusion Criteria for smokers:

  • The patient has given his/her signed, informed consent
  • Forced expiratory volume in 1 second / forced vital capacity > 0.7 [FEV1/FVC > 0.7]
  • FEV1 > 80% of predicted value
  • Exclusion of other respiratory pathologies, based on anamnesis, computed tomography (absence of extensive emphysema lesions defined by the presence of less than <5% relative surface area occupied by densities less than 910 UH (measured on millimeter cuts)) and respiratory function tests (Residual Volume <120%, Diffusion Capacity for Carbon Monoxide > 60% and Total Pulmonary Capacity> 120%) and transthoracic ultrasound (normal),
  • Smoking >40 pack-years, ongoing or weaned
  • Absence of exacerbation or intercurrent infectious episode for at least 4 weeks at time of inclusion
  • Medical indication for a bronchial fibroscopy (indication validated by the physician in charge of the patient and the study investigating physician): pulmonary peripheral nodule exploration with computed tomography, interventional endoscopy for emphysema reduction, removal of foreign bodies, other indications.
  • Absence of contraindications for bronchial biopsy (left to physician's discretion): not limited to: regular intake of anticoagulants or anti-platelet aggregation, hemostasis abnormalities

Exclusion Criteria:

  • Contra-indication for bronchial fibroscopy and cutaneous biopsy
  • Deficiency in α-1 antitrypsin
  • Significant bronchiectasis on chest computed tomography scan
  • Colonization of the airways by Pseudomonas Aeroginosa or Aspergillus
  • Chemotherapy or other cytotoxic treatments in the last 12 months
  • Systemic corticotherapy in the 4 weeks prior to inclusion
  • Long-term antibiotic treatment, notably by macrolides
  • Any other treatment that may affect the bronchial epithelium, this being left to the discretion of the investigating physician
  • Consumer of illicit drugs or alcohol
  • Participant in an exclusion period determined by a previous study
  • Subject not affiliated with, or not beneficiary of, a social security plan.
  • Pregnant or nursing women according to Article L1121-5 of the Public Health Code.
  • Vulnerable persons according to Article L1121-6 of the Public Health Code
  • An adult who is protected or incapable of giving consent in accordance with Article L1121-8 of the Public Health Code
  • Subject deprived of freedom by judicial or administrative decision.
  • Those patients for whom two epithelia cultures (1 from bronchial biopsy ("ALI") and 1 from fibroblast reprogrammation of redifferentiated iPS ("iALI")) were not obtained will be excluded (post-inclusion).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03181204


Contacts
Layout table for location contacts
Contact: Arnaud Bourdin, MD,PhD +33.(0)4.67.33.61.26 a-bourdin@chu-montpellier.fr

Locations
Layout table for location information
France
Centre Hospitalier Universitaire de Montpellier Recruiting
Montpellier, France, 34295
Principal Investigator: Arnaud Bourdin, MD, PhD         
Sponsors and Collaborators
University Hospital, Montpellier
Investigators
Layout table for investigator information
Study Director: Arnaud Bourdin, MD, PhD University Hospital, Montpellier

Additional Information:
Layout table for additonal information
Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT03181204     History of Changes
Other Study ID Numbers: 9791
2017-A00252-51 ( Other Identifier: RCB number )
First Posted: June 8, 2017    Key Record Dates
Last Update Posted: June 11, 2018
Last Verified: June 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Respiratory Tract Diseases
Lung Diseases, Obstructive
Disease Attributes
Pathologic Processes